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CASE REPORT
Polyneuropathy in a Patient with Malignant Pleural
Mesothelioma
A Paraneoplastic Syndrome
Cecilia Bech, MD, and Jens Benn Sørensen, MD, DMSc, MPA
Abstract: Paraneoplastic syndromes have only been reported in
malignant pleural mesothelioma (MPM) in a few cases. In this case,
we describe a 57-year-old man with MPM who developed sensory-
motor polyneuropathy 18 days after diagnosis. Thorough endocri-
nological, neurological, and paraclinical examinations gave no
explanation of the symptoms, and paraneoplasia was therefore
suspected. The patient was treated with immunoglobulin and pred-
nisolone, and this resulted in subjective, objective, and paraclinical
improvement of the symptoms. We therefore suggest that polyneu-
ropathy is a possible paraneoplastic syndrome in MPM.
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(J Thorac Oncol. 2008;3: 1359–1360)
A 57-year-old healthy man was referred to the departmentof oncology for palliative chemotherapy of unresectable
malignant pleural mesothelioma (MPM) of epithelial sub-
type, localized to the left hemithorax. There was no previous
history of peripheral neuropathy or central nervous system
disorders. The patient was generally in good clinical condi-
tion. He developed muscle and joint pain in all four extrem-
ities, paresthesia and sensory loss in the distal parts of arms
and legs, and reduced force in especially the lower extremi-
ties 10 days before the first consultation in the oncological
department and 18 days after histopathologic diagnosis.
Walking became severely impaired, and the patient subse-
quently used wheelchair.
Magnetic resonance imaging of the entire spine showed
no signs of medullary compression or epidural tumor growth.
Electromyography showed severe sensory-motor polyneurop-
athy of demyelinizing type in all four extremities. Diabetes,
hypothyroidism, and electrolytic disorders were ruled out.
A lumbal puncture was without signs of infection or
malignant cells and with normal concentration of protein and
glucose. Paraneoplastic markers in spinal fluid (amphyiphy-
sin 1-antibody, purkinje-cell antibody Yo [IgG], Ri-antibody
[Nova 1], and neuron core antibody Hu [IgG]) were all
negative. Screening package of peripheral blood with im-
munofixation IgA, IgG, IgM, kappa, and lambda showed
weakly expressed monoclonal gammopathy type IgG lambda.
Antimyelin-associated glycoprotein and antisulfoglucuronyl-
paragloboside were within the reference range, and Hu-D-
antibody was negative.
The neurologic department judged these findings to
suggest paraneoplastic peripheral neuropathy, and pulse treat-
ment with methylprednisolone succinate, 1 g/d and immun-
globulin 0.4/kg/d for 5 days was initiated. The symptoms
declined subjectively and objectively after 3 days of treat-
ment, and the patient could walk with support after 1 week.
Chemotherapy with carboplatin and vinorelbine every
3 weeks was initiated 6 days after pulse treatment and was
administered for four courses, after which progression oc-
curred. Treatment strategy was shifted to pemetrexed every 3
weeks, which the patient still receives. So far, the response to
the treatment is no-change after four courses.
The patient has regained sensory and motor function
almost completely at neurologic examination 5 months after
the first admission without any reinduction of the pulse
treatment. A new electromyography 27 weeks after the start
of first line chemotherapy showed improvement in especially
motor response whereas sensory amplitudes were still re-
duced. This may, however, also be due to neurologic sequelae
to the first-line chemotherapy.
DISCUSSION
Paraneoplastic syndromes are signs and symptoms of a
tumor seen distant from the primary site or metastases. The
manifestations may be endocrinologic, hematologic, gastro-
intestinal, renal, cutaneous, or neurologic and may occur in
many different types of cancers, at varying frequencies.1
Lung cancer, and in particular small cell lung cancer (SCLC),
is often associated with paraneoplastic syndromes, often
caused by ectopic hormone production, such as Cushing
syndrome (5% of SCLC) or syndrome of inappropriate anti-
diuretic hormone production (15% of SCLC). Another fre-
quent type of paraneoplasia in SCLC is mediated through
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antibodies, resulting in neurologic syndromes, such as Lam-
bert-Eaton myasthenic syndrome (antibodies against voltage-
gated calcium channels). Different other neurologic syn-
dromes are associated with the anti-Hu antibody, such as
cerebellar degeneration, limbic encephalitis, opsoclonus-my-
oclonus, and diffuse encephalitis with multifocal neurologic
symptoms (1% or less each).2,3
In contrast, paraneoplasia is rarely reported in MPM.
Paraneoplastic syndromes such as syndrome of inappropriate
antidiuretic hormone production,4,5 nephrotic syndrome,6 and
antiphospholipid syndrome7 have been reported in MPM.
Also, subacute cerebellar degeneration has been observed,8 but
to our best knowledge, the current case of peripheral sensory-
motor paraneoplastic syndrome is the first reported in MPM.
No other explanation for the symptoms in the current
case were discovered despite thorough endocrinological, neu-
rologic, and paraclinical examinations. The electromyelogra-
phy confirmed that a measurable reduced nerve conduction
was present, and that these changes declined after treatment
with glucocorticoid and immunoglobulin together with the pa-
tients’ subjective and objective symptoms. The fact that the
condition was nearly completely reversible strengthens the
suspicion that the symptoms were caused by a paraneoplastic
syndrome. We therefore suggest that sensory-motor polyneu-
ropathy is a possible paraneoplastic syndrome in MPM.
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